Zansecimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized and engineered immunoglobulin G4 (IgG4) isotype monoclonal antibody against the proangiogenic cytokine angiopoietin 2 (Ang2), with potential anti-angiogenic activity. Upon administration, zansecimab targets and binds to Ang2. This prevents the binding of Ang2 to its endothelial cell-specific receptor TEK tyrosine kinase (Tie2). This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation. In addition, Ang2 is elevated in acute respiratory distress syndrome (ARDS), and targeting Ang2 may prevent or slow ARDS progression.

**Synonyms:** - LY 3127804 - LY-3127804 - LY3127804 - ZANSECIMAB